Article Text
PDFMiscellaneous
Correction: Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Statistics from Altmetric.com
Dougados M, Wei JC-C, Landewé R, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann of Rheum Dis 2020;79:176-85.
The numbers in table 1 and supplementary Table 3 were inadvertently sourced from outdated documents. The correct details are shown as:
View this table:
Table 1
Week 16* and 52 efficacy endpoints for patients treated continuously with ixekizumab: COAST-V and COAST-W (ITT population: NRI, modified baseline observation carried forward)
View this table:
Table 3
Week 16 and 52 efficacy endpoints for patients treated continuously with ixekizumab: COAST-V and COAST-W (ITT population: observed data)